Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile
Company provides 2026 corporate outlook highlighting multiple clinical catalysts across first-in-class cardioendocrine pipeline
MAR002 Phase 1 Data: Robust, durable IGF-1 suppression supports potential for biweekly to monthly dosing; Phase 2/3 study initiation expected mid-2026
MAR001 Phase 2b TYDAL-TIMI 78 Study Enrollment Nearing Completion: multiple data readouts expected throughout 2026; advancing half-life-extended MAR001-HLE designed for infrequent, low-volume subcutaneous dosing toward Phase 3 readiness
Pipeline Expansion: Advancing next-generation siRNA portfolio with development candidate nomination(s) expected in 2026
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced positive topline results from its first-in-human Phase 1 study of MAR002, a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor (GHR) for the treatment of acromegaly. The company also highlighted key pipeline milestones expected in 2026 – including for its lead cardiometabolic program, MAR001, a first-in-class, subcutaneously delivered monoclonal antibody designed to block the activity of ANGPTL4, a genetically validated driver of remnant cholesterol and atherosclerotic cardiovascular disease (ASCVD) risk.
“The MAR002 data provide clear proof-of-mechanism and underscore our ability to translate human genetic insights into highly differentiated clinical candidates,” said Josh Lehrer, M.D., chief executive officer of Marea Therapeutics. “With MAR002 moving toward a registrational study, MAR001 nearing a major Phase 2b readout, and our siRNA platform expanding, Marea is uniquely positioned to redefine the treatment of cardioendocrine diseases. 2026 will be a catalyst-rich year as we execute across our entire portfolio.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?